Detalles de la búsqueda
1.
Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA Registry.
Haematologica;
2024 04 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38572549
2.
Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registry.
Hematol Oncol;
42(1): e3240, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38050405
3.
The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey.
Leuk Lymphoma;
65(2): 199-208, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37966980
4.
Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings.
Int J Infect Dis;
137: 98-110, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37863310
5.
Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry.
Res Pract Thromb Haemost;
7(6): 102185, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37720483
6.
Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry.
Int J Antimicrob Agents;
62(4): 106952, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37582478
7.
Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in "Real-Life": The SEIFEM Experience.
Cancers (Basel);
15(13)2023 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37444567
8.
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry.
EClinicalMedicine;
58: 101939, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37041967
9.
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry.
J Hematol Oncol;
16(1): 32, 2023 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37005697
10.
Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry.
Front Immunol;
14: 1125030, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36911708
11.
Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry.
Ther Adv Hematol;
14: 20406207231154706, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36923264
12.
Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report.
Hemasphere;
6(11): e789, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36310756
13.
High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study.
J Fungi (Basel);
8(6)2022 May 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-35736066
14.
COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey.
Blood Adv;
6(13): 3870-3874, 2022 07 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35500220
15.
Mixed T cell CHIMERISM in bone marrow at day+30 after allogeneic stem cell transplantation: Correlation with acute GVHD grades III-IV and no impact on relapse and overall survival.
Eur J Haematol;
109(1): 83-89, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35389543
16.
Invasive aspergillosis in relapsed/refractory acute myeloid leukaemia patients: Results from SEIFEM 2016-B survey.
Mycoses;
65(2): 171-177, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34695256
17.
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA).
J Hematol Oncol;
14(1): 168, 2021 10 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-34649563
18.
Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience.
Front Oncol;
11: 740079, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34616684
19.
Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper.
Crit Rev Oncol Hematol;
158: 103203, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33388453
20.
Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study.
Br J Haematol;
193(2): 316-324, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33058237